RxDoctor Payments Data

Heather Moon

Adult Health · Soldotna, AKNPI 1205547205

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 38.9% of the total. That places this record below the midpoint for adult health clinicians in AK, where the typical reported total is $560.

$560in general payments, 2019–2025

Across 21 payments — averaging $26.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$218
  • Pfizer$41
  • Novo Nordisk$39
  • Teva Pharmaceuticals USA, Inc.$39
  • Exact Sciences$38
  • Lilly USA, LLC$37
  • plus $148 from 6 others

What the payments were for

  • Food & beverage$560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$560 in reported general payments places this provider in the 50th percentile of 22 adult health providers in Alaska.

See all adult health providers in Alaska

Medicare billing

Part B allowed, 2024
$34,903
Medicare patients
68
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$21,448
MounjaroTirzepatide11$19,720
Estradiol15$908
Celecoxib19$814
Gabapentin30$789
Atorvastatin Calcium51$772
Alendronate Sodium16$633
Pantoprazole Sodium22$505
Levothyroxine Sodium33$274
Amlodipine Besylate30$231
Donepezil Hcl12$218
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$218
Losartan Potassium24$206
Allopurinol12$125
Zolpidem Tartrate14$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$39$21,44823 claims
Lilly USA, LLCMounjaro$37$19,72011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 22 adult health providers in Alaska.

Other adult health in Soldotna

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →